In high-containment oral solid-dose manufacturing, exatecan mesylate is processed as a cytotoxic camptothecin analogue using containment isolators or split-valve closed transfer devices under a site-specific occupational exposure limit derived from the NIOSH hazardous drug list. For a 1 mg immediate-release tablet, dry granulation by roller compaction is preferred over aqueous wet granulation because the mesylate salt and the camptothecin-derived lactone ring are susceptible to moisture-driven hydrolysis and pH-mediated carboxylate conversion. A representative roller-compacted blend contains 1.0 wt% exatecan mesylate, 0.5–1.0 wt% sodium stearyl fumarate as intragranular lubricant, 2.0 wt% croscarmellose sodium intragranularly, 15–20 wt% microcrystalline cellulose, and lactose monohydrate q.s. to 100 mg core weight. The pre-blend is passed through a 0.8 mm sieve, roller-compacted at roll force 6–12 kN/cm, milled through a 0.8–1.25 mm screen, and blended with extragranular croscarmellose sodium 2.0 wt% and sodium stearyl fumarate 1.0 wt%. Tablets are compressed on a 39-station rotary press with 6 mm biconvex tooling at main compression force 8–15 kN; acceptance targets are tablet hardness 80–120 N, friability not more than 1.0% by USP <1216>, disintegration time not more than 15 min in 0.01 N hydrochloric acid at 37 °C by USP <701>, and content uniformity with acceptance value not more than 15.0 by USP <905>. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.01 N hydrochloric acid because the lactone form of camptothecin analogues predominates under acidic pH; release specification is not less than 80% dissolved at 30 min. Published process data for this specific API in roller-compacted tablet configurations are limited, so transfer from laboratory scale to pilot scale requires confirmation of granule density, fines content below 150 µm, and moisture content not exceeding 2.5% by USP <731>. Terminal product is a film-coated immediate-release tablet with 1 mg label claim, intended for oral administration under oncologic supervision.

What Limits Direct Compression of Exatecan Mesylate in Single-Dose Tablet Lines?

The principal limitation in direct compression is blend segregation driven by particle size and density differences between the API and common direct-compression excipients. Exatecan mesylate batches with a flow function coefficient below 4, measured by shear cell according to USP <1174>, require glidant addition or geometric dilution; otherwise weight variation exceeds ±5% on 5 mm shallow concave tooling. A direct-compression formulation is feasible when the API fraction is micronized to a d90 below 75 µm, determined by laser diffraction according to USP <429>, and pre-blended with spray-dried lactose monohydrate at 65–75 wt%, microcrystalline cellulose at 20–25 wt%, croscarmellose sodium at 2–4 wt%, colloidal silicon dioxide at 0.5–1.5 wt%, and magnesium stearate at 0.5–1.0 wt%. The blend is mixed in a 300 L bin blender at 10–12 rpm for a time determined by stratified blend uniformity sampling under USP <905>; over-lubrication reduces tablet breaking force, measured as crushing strength by USP <1216>, and contact time with magnesium stearate beyond 5–10 min after final addition should be avoided. Compression is performed on a 10-station instrumented press with precompression force 2–4 kN and main compression force 6–12 kN; weight target is 80 mg for a 1 mg dose. Tablet hardness is controlled at 50–90 N, friability not more than 1.0%, and disintegration not more than 10 min in 0.01 N hydrochloric acid. Direct compression is not recommended for high-dose oral formulations above 5 mg because API-to-excipient adhesiveness increases sticking risk on upper punches; in such cases roller compaction or wet granulation is the fallback route. This segment yields uncoated or film-coated single-dose tablets, with post-compression dedusting and metal detection at the press discharge.

Hard Capsule Filling with Lactose-MCC Granules at 1 mg Dose Strength

Hard capsule manufacturing for exatecan mesylate is used when dose flexibility below 1 mg or swallowing ease is required. The fill material is a free-flowing granule prepared by low-shear wet granulation of the API with lactose monohydrate 70–85 wt%, microcrystalline cellulose 10–15 wt%, pregelatinized starch 5–10 wt%, croscarmellose sodium 2–3 wt%, and povidone K30 2–5 wt% as binder; purified water is added to achieve a wet mass, and the granulate is dried to loss on drying not more than 2.0% by USP <731>. The dried granulate is milled through a 0.8 mm conical screen, lubricated with magnesium stearate 0.5 wt%, and filled into size 3 or 4 hard gelatin or hydroxypropyl methylcellulose capsules on a dosator or tamping-pin capsule filler. In-process weight control uses a 100% checkweigher or automated weight sorting with acceptance of ±5% individual fill weight; batch sampling for content uniformity follows USP <905>. Dissolution testing is performed with USP <711> Apparatus 1 at 100 rpm in 900 mL of pH 4.5 acetate buffer, where the lactone-carboxylate equilibrium is controlled; release specification is not less than 80% dissolved at 45 min. Finished capsules are dedusted, visually inspected for splits and dents, and packaged in cold-form aluminium-aluminium blisters if moisture sensitivity data indicate a requirement for a high-barrier container. Terminal product is a 1 mg capsule for oral administration.

For oral granules packed in single-dose sachets, the formulation route shifts toward fluid-bed granulation to produce spherical granules with low friability and high redispersibility in aqueous vehicles. A representative sachet batch contains exatecan mesylate 1.0 wt%, mannitol 40–60 wt%, microcrystalline cellulose 15–25 wt%, crospovidone 2–4 wt%, citric acid 2–5 wt% to maintain an acidic microenvironment, and hydroxypropyl cellulose 3–6 wt% as binder. Granulation is performed in a fluid-bed processor with top-spray nozzle, inlet air temperature 60–70 °C, product temperature 30–35 °C, spray rate 15–25 g/min, and atomizing air pressure 1.5–2.0 bar. The granules are dried to loss on drying not more than 2.5% by USP <731>, sieved through a 1.0 mm screen, and filled into paper-aluminium-polyethylene sachets on an auger filler with fill weight target 500 mg and acceptance ±5%. Sachet content uniformity is assessed by USP <905>; fill weight variation is monitored by in-process weighing at 15 min intervals. For reconstitution, the sachet contents are dispersed in 50 mL purified water immediately before administration; suspension uniformity and redispersibility are verified by measuring the delivered dose after three inversions of a 250 mL graduated bottle. Finished product is a single-dose sachet of granules for oral suspension, with a 1 mg dose, packaged in child-resistant outer cartons. This granule route avoids aqueous exposure during bulk storage and is used where tablet or capsule swallowing is contraindicated.

When Lyophilized Exatecan Mesylate Cakes Are Reconstructed in 0.9% Sodium Chloride Injection

Injectable lyophilized product development is governed by the pH-dependent aqueous solubility of the mesylate salt and the need to maintain the active lactone fraction during freezing, primary drying, and storage. The pre-lyophilization solution is prepared in Water for Injection at an exatecan mesylate concentration of 0.5–2.0 mg/mL, with mannitol 40–60 mg/mL as crystalline bulking agent, trehalose dihydrate 10–20 mg/mL as lyoprotectant, and hydrochloric acid or sodium hydroxide for pH adjustment to the formulation-specific target between pH 3.0 and 4.5. The solution is prefiltered through a 0.45 µm polyvinylidene fluoride membrane, sterilizing-filtered through a 0.22 µm membrane in a Grade A isolator, and filled into 10R type I borosilicate vials at 5 mL nominal fill volume. Freeze-drying cycle design uses differential scanning calorimetry and freeze-dry microscopy to identify the glass transition temperature of the maximally concentrated solution and collapse temperature; shelf freezing is conducted at −40 °C for 2 h, with an optional annealing step at −20 °C for 2 h to promote mannitol crystallization. Primary drying is started at shelf temperature −20 °C and chamber pressure 0.15 mbar; product temperature is maintained below the collapse temperature using vials with external thermocouples and comparative Pirani/capacitance manometer readings to determine endpoint. Secondary drying is performed at +25 °C for 12 h at 0.05 mbar, targeting residual moisture not more than 1.0% by Karl Fischer titration. Published cycle parameters for this specific API are limited; therefore, formulation-specific thermal characterization is required before scale-up. The finished product is a sterile lyophilized cake for single-dose intravenous or subcutaneous injection, reconstituted with 5 mL of 0.9% sodium chloride injection to a final concentration suitable for administration. Release testing includes sterility USP <71>, bacterial endotoxins USP <85>, particulate matter USP <788>, visible particulates USP <790>, content uniformity by USP <905>, and residual moisture by USP <921> water determination.

Sterile Solution Manufacturing Through 0.22 µm Hydrophilic PVDF Filtration

Aseptic solution manufacturing is used for ready-to-administer injectable presentations when lyophilization is not required or where hospital pharmacy admixture is simplified. Exatecan mesylate is dissolved in Water for Injection under nitrogen overlay to minimize oxidative degradation; sodium chloride is added to adjust tonicity to 280–310 mOsmol/kg by USP <785>, and pH is adjusted to the approved target with hydrochloric acid or sodium hydroxide. The bulk solution is held under nitrogen and filtered through a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm hydrophilic PVDF sterilizing-grade filter. Filter integrity testing is performed pre-use and post-use by bubble point or diffusive flow according to ASTM F838-20; the post-use test must be passed before batch release. The solution is filled under Grade A laminar flow into 10 mL type I glass vials with 5 mL or 10 mL fill volume, stoppered with fluoropolymer-coated elastomeric closures, and sealed with aluminum flip-off caps. Terminal sterilization by moist heat is not applied because of the heat sensitivity of the camptothecin-derived lactone ring observed in forced degradation studies under ICH Q1A and ICH Q1B; therefore, aseptic process validation includes three consecutive media fills, environmental monitoring under EU GMP Annex 1, and operator qualification. In-process controls include pH, filter integrity, fill volume check by in-line weight or volume, bioburden before sterilizing filtration not more than 10 CFU/100 mL, and visual inspection for particulate matter. Release testing includes sterility USP <71>, bacterial endotoxins USP <85>, subvisible particulate matter USP <788>, visible particulate USP <790>, assay by HPLC USP <621>, related substances by USP <621>, and residual solvents USP <467>. The terminal product is a sterile solution for injection, supplied as single-dose vials, for intravenous administration after dilution in compatible infusion fluids.